Catalyst Calendar

AtriCure [ATRC]

AtriCure [ATRC] — Catalyst Calendar

As of 2026-07-29. Every date is disclosed by the company. No readout date is inferred or fabricated.

Dated

Date	Event	Why it matters	Confirms / refutes
Around end-2026 ("late December or early January")	BoxX-NoAF full enrollment — 960 patients	Carrel, Q1 & Q2 2026: >500 enrolled at Q2 2026, past the 50% mark, "well ahead of our original plan" (~1 year early). Gates the readout.	The H1 2027 readout timing
H1 2027	BoxX-NoAF DATA READOUT	The single most important dated event in the name. Carrel, Q2 2026 prepared remarks: "Based on our current trajectory, we are positioned for clinical trial data readouts in the first half of 2027." Primary endpoint is post-operative AF measured 30 days after the last patient is enrolled — the short endpoint is what makes the timeline credible.	The prophylactic-ablation market-expansion thesis; the Valuation Criteria's required 18.91% CAGR
2026 (H2)	FDA IDE submission for a next device	Carrel, Q1 2026 Q&A: "submission to the FDA later on this year, acceptance of the IDE and then beginning to enroll as we kind of look into 2027."	Pipeline beyond the two landmark trials
2027	New product release	Carrel, Q4 2025 Q&A: "We have another new product slated for release in 2027." Product not named by the company; not named here.	Franchise refresh
2027	STS post-operative AF quality measure moves to enforcement	Carrel, Q1 2026 Q&A: "They anticipate rolling this out with more enforcement in 2027, at which point it will be measured and recorded in the STS database… We anticipate an uplift in adoption beginning in 2027 and continuing into 2028 and beyond, which should be a multi-year positive for the ablation side." Specifics "still being finalized by STS."	The ablation adoption ramp
2027 (early)	Clinical trials begin on the next-generation programme discussed at the Analyst Day	Carrel, Q3 2025 Q&A: "the next step after that… is to go into clinical trials likely in the early part of 2027."	Long-dated pipeline
Q3 2026 (mid-Oct, not announced)	Q3 2026 earnings	First test of the raised FY2026 adjusted EBITDA guide ($85–89m) and of the guided back-half reimbursement pressure.	FY2026 guidance

NOT DISCLOSED — stated as absent rather than estimated

LeAAPS data readout. Enrollment of 6,573 patients across 137 sites completed July 2025, but AtriCure has disclosed no readout date, and has explicitly declined to. Carrel, Q4 2025 Q&A: "To address your question about the timing of the LeAAPS data, we won't be sharing specific data on when we reach the 50% mark." Q2 2026 offers only "as we get closer to the clinical trial outcomes." This is an event-driven trial. No date exists to put in this calendar, so none is put in it. It is the larger of the two prizes — the only trial testing prophylactic stroke reduction with the AtriClip alone — and it is entirely undated.
"DEEP AF." Named in the task brief but not an AtriCure programme: it appears twice in fourteen quarters of transcripts, both times in 2023, both incidental, and zero times in the last ten quarters. No DEEP AF milestone is listed because none exists to list.

Occurred this cycle

Date	Move	Note
2025-04-30	−13.68%
2026-01-15	+10.94%
2026-02-11	−13.11%
2026-05 → 2026-07	$27.70 → $40.89, +47.6%	Q2 2026 beat: revenue $153.6m, adjusted EBITDA $27.3m (+78%), GAAP net income $9m, FY26 adjusted EBITDA guide raised to $85–89m. This is the re-rating the 12-month target says has already happened.

Generated from each name's analysis.json. Figures are research output, not investment advice. Gaps are shown as “—” rather than filled: a missing input is recorded as indeterminate, never estimated.